ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline, Sanofi and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

GlaxoSmithKline×Sanofi×Novartis×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineSanofiNovartis
studies on the registry4,1982,4253,902
open to participants now135104212
phase 3 studies under way766194
reach primary completion within a year6664128
programswith a study of their own in two years88+17 named only80+12 named only77+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineSanofiNovartis
Phase 1

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
28%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%
Phase 3

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 59 in all. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineSanofiNovartis
Carcinoma, Non-Small-Cell Lungall three · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopicall three · compare here

GlaxoSmithKline in Dermatitis, Atopic: 2 programs

  1. camlipixantphase 3
  2. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Dermatitis, Atopic in search

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Arthritis, Rheumatoidall three · compare here

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Lupus Erythematosus, Systemicall three · compare here

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaall three · compare here

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Malariaall three · compare here

GlaxoSmithKline in Malaria: 2 programs

  1. as01ephase 2
  2. Dolutegravirapproved, new study

Their studies: GlaxoSmithKline’s studies of Malaria in search

Sanofi in Malaria: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Malaria in search

Novartis in Malaria: 3 programs

  1. cipargaminphase 2
  2. ganaplacidephase 2
  3. Coartem® Babyapproved, new study

Their studies: Novartis’s studies of Malaria in search

Colorectal Neoplasmsall three · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Alzheimer Diseaseall three · compare here

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

Sanofi in Alzheimer Disease: 1 program

  1. SAR448851phase 2

Their studies: Sanofi’s studies of Alzheimer Disease in search

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

Anemia, Sickle Cellall three · compare here

GlaxoSmithKline in Anemia, Sickle Cell: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Anemia, Sickle Cell in search

Sanofi in Anemia, Sickle Cell: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Anemia, Sickle Cell in search

Novartis in Anemia, Sickle Cell: 1 program

  1. ITU512phase 2

Their studies: Novartis’s studies of Anemia, Sickle Cell in search

Chronic Urticariaall three · compare here

GlaxoSmithKline in Chronic Urticaria: 1 program

  1. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Chronic Urticaria in search

Sanofi in Chronic Urticaria: 1 program

  1. BLU-808phase 2

Their studies: Sanofi’s studies of Chronic Urticaria in search

Novartis in Chronic Urticaria: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Chronic Urticaria in search

Polycystic Kidney, Autosomal Dominantall three · compare here

GlaxoSmithKline in Polycystic Kidney, Autosomal Dominant: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Polycystic Kidney, Autosomal Dominant in search

Sanofi in Polycystic Kidney, Autosomal Dominant: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Polycystic Kidney, Autosomal Dominant in search

Novartis in Polycystic Kidney, Autosomal Dominant: 1 program

  1. farabursenphase 1

Their studies: Novartis’s studies of Polycystic Kidney, Autosomal Dominant in search

Prostatic Neoplasms2 of 3 · compare here–

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Influenza, Human2 of 3 · compare here–
Respiratory Syncytial Virus Infections2 of 3 · compare here

GlaxoSmithKline in Respiratory Syncytial Virus Infections: 5 programs

  1. arexvyphase 3
  2. Adjuvanted RSVPreF3 vaccinephase 2
  3. hMPV_Y low dose vaccinephase 2
  4. RSV/hMPV_V low dose vaccinephase 2
  5. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Respiratory Syncytial Virus Infections in search

Sanofi in Respiratory Syncytial Virus Infections: 9 programs

  1. RSVt Vaccinephase 3
  2. RSV+HMPV vaccinephase 2
  3. RSV vaccine formulation 1 dosephase 2
  4. H5 Flu IMP 2phase 1
  5. Inosine Monophosphatephase 1

and 4 more — sign in to see them all

Their studies: Sanofi’s studies of Respiratory Syncytial Virus Infections in search

–
Asthma2 of 3 · compare here

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

–
Breast Neoplasms2 of 3 · compare here

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

–

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Neoplasms2 of 3 · compare here–

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

Small Cell Lung Carcinoma2 of 3 · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

–
Malaria, Falciparum2 of 3 · compare here

GlaxoSmithKline in Malaria, Falciparum: 3 programs

  1. GSK3772701phase 2
  2. GSK4425689Aphase 1
  3. GSK4024484Cphase 1

Their studies: GlaxoSmithKline’s studies of Malaria, Falciparum in search

–

Novartis in Malaria, Falciparum: 4 programs

  1. ganaplacidephase 3
  2. cipargaminphase 2
  3. INE963phase 2
  4. ganaplacidephase 2

Their studies: Novartis’s studies of Malaria, Falciparum in search

Ovarian Neoplasms2 of 3 · compare here

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

–

Novartis in Ovarian Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Ovarian Neoplasms in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

–
Cardiovascular Diseases2 of 3 · compare here

GlaxoSmithKline in Cardiovascular Diseases: 3 programs

  1. Adjuvanted RSVPreF3 vaccinephase 2
  2. Adjuvanted RZV vaccinephase 2
  3. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Cardiovascular Diseases in search

–

Novartis in Cardiovascular Diseases: 2 programs

  1. pelacarsenphase 3
  2. DII235phase 2

Their studies: Novartis’s studies of Cardiovascular Diseases in search

Colitis, Ulcerative2 of 3 · compare here

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

–
Hidradenitis Suppurativa2 of 3 · compare here–

Sanofi in Hidradenitis Suppurativa: 2 programs

  1. brivekimigphase 2
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Hidradenitis Suppurativa in search

Novartis in Hidradenitis Suppurativa: 3 programs

  1. remibrutinibphase 3
  2. arumakimigphase 2
  3. secukinumabapproved, new study

Their studies: Novartis’s studies of Hidradenitis Suppurativa in search

Nasal Polyps2 of 3 · compare here

GlaxoSmithKline in Nasal Polyps: 2 programs

  1. felcorekibartphase 3
  2. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Nasal Polyps in search

Sanofi in Nasal Polyps: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Nasal Polyps in search

–
Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here–

Sanofi in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Novartis in Purpura, Thrombocytopenic, Idiopathic: 3 programs

  1. ianalumabphase 3
  2. Thrombopoietin Receptor Agonistphase 2
  3. eltrombopagapproved, new study

Their studies: Novartis’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Immune System Diseases2 of 3 · compare here

GlaxoSmithKline in Immune System Diseases: 2 programs

  1. isatuximabphase 2
  2. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Immune System Diseases in search

Sanofi in Immune System Diseases: 2 programs

  1. amlitelimabphase 3
  2. belumosudilapproved, new study

Their studies: Sanofi’s studies of Immune System Diseases in search

–
Psoriasis2 of 3 · compare here–

Sanofi in Psoriasis: 3 programs

  1. balinatunfibphase 2
  2. belumosudilapproved, new study
  3. teplizumabapproved, new study

Their studies: Sanofi’s studies of Psoriasis in search

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Anemia, Hemolytic, Autoimmune2 of 3 · compare here

GlaxoSmithKline in Anemia, Hemolytic, Autoimmune: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Anemia, Hemolytic, Autoimmune in search

Sanofi in Anemia, Hemolytic, Autoimmune: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Anemia, Hemolytic, Autoimmune in search

–
Bronchiectasis2 of 3 · compare here

GlaxoSmithKline in Bronchiectasis: 1 program

  1. GSK3862995Bphase 2

Their studies: GlaxoSmithKline’s studies of Bronchiectasis in search

Sanofi in Bronchiectasis: 2 programs

  1. itepekimabphase 3
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Bronchiectasis in search

–
Diphtheria2 of 3 · compare here

GlaxoSmithKline in Diphtheria: 2 programs

  1. Pentetic Acidphase 3
  2. dTpa vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Diphtheria in search

Sanofi in Diphtheria: 1 program

  1. DTaP-IPV-HB-PRP~T combined vaccinephase 3

Their studies: Sanofi’s studies of Diphtheria in search

–
Hypercholesterolemia2 of 3 · compare here–

Sanofi in Hypercholesterolemia: 1 program

  1. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Hypercholesterolemia in search

Novartis in Hypercholesterolemia: 2 programs

  1. QCZ484phase 2
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Hypercholesterolemia in search

Lymphoma, B-Cell2 of 3 · compare here–

Sanofi in Lymphoma, B-Cell: 1 program

  1. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lymphoma, B-Cell in search

Measles2 of 3 · compare here

GlaxoSmithKline in Measles: 2 programs

  1. MMRVNSphase 3
  2. MMRVNS vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Measles in search

Sanofi in Measles: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Measles in search

–
Meningococcal Infections2 of 3 · compare here

GlaxoSmithKline in Meningococcal Infections: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Meningococcal Infections in search

–
Myotonic Dystrophy2 of 3 · compare here–

Sanofi in Myotonic Dystrophy: 1 program

  1. SAR446268phase 2

Their studies: Sanofi’s studies of Myotonic Dystrophy in search

Novartis in Myotonic Dystrophy: 2 programs

  1. delpacibart zotadirsenphase 3
  2. AOC 1001phase 3

Their studies: Novartis’s studies of Myotonic Dystrophy in search

Primary Myelofibrosis2 of 3 · compare here

GlaxoSmithKline in Primary Myelofibrosis: 1 program

  1. momelotinibphase 3

Their studies: GlaxoSmithKline’s studies of Primary Myelofibrosis in search

–

Novartis in Primary Myelofibrosis: 2 programs

  1. pelabresibphase 3
  2. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Primary Myelofibrosis in search

Sjogren's Syndrome2 of 3 · compare here–

Sanofi in Sjogren's Syndrome: 1 program

  1. frexalimabphase 3

Their studies: Sanofi’s studies of Sjogren's Syndrome in search

Novartis in Sjogren's Syndrome: 2 programs

  1. ianalumabphase 3
  2. DDY391phase 2

Their studies: Novartis’s studies of Sjogren's Syndrome in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

Novartis in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Squamous Cell Carcinoma of Head and Neck in search

Streptococcal Infections2 of 3 · compare here

GlaxoSmithKline in Streptococcal Infections: 2 programs

  1. Low dose Strep A Alumphase 1
  2. Low dose Strep A AS37phase 1

Their studies: GlaxoSmithKline’s studies of Streptococcal Infections in search

Sanofi in Streptococcal Infections: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Streptococcal Infections in search

–
Arthritis, Juvenile2 of 3 · compare here–

Sanofi in Arthritis, Juvenile: 1 program

  1. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Juvenile in search

Novartis in Arthritis, Juvenile: 1 program

  1. arumakimigphase 2

Their studies: Novartis’s studies of Arthritis, Juvenile in search

Autoimmune Diseases2 of 3 · compare here

GlaxoSmithKline in Autoimmune Diseases: 1 program

  1. belantamabphase 2

Their studies: GlaxoSmithKline’s studies of Autoimmune Diseases in search

Sanofi in Autoimmune Diseases: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Autoimmune Diseases in search

–
Bronchiolitis Obliterans Syndrome2 of 3 · compare here–

Sanofi in Bronchiolitis Obliterans Syndrome: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Bronchiolitis Obliterans Syndrome in search

Novartis in Bronchiolitis Obliterans Syndrome: 1 program

  1. asciminibapproved, new study

Their studies: Novartis’s studies of Bronchiolitis Obliterans Syndrome in search

Carcinoma, Renal Cell2 of 3 · compare here–

Sanofi in Carcinoma, Renal Cell: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Carcinoma, Renal Cell in search

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Diabetes Mellitus, Type 22 of 3 · compare here

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

–
Gastrointestinal Stromal Tumors2 of 3 · compare here

GlaxoSmithKline in Gastrointestinal Stromal Tumors: 1 program

  1. velzatinibphase 3

Their studies: GlaxoSmithKline’s studies of Gastrointestinal Stromal Tumors in search

Sanofi in Gastrointestinal Stromal Tumors: 1 program

  1. Avapritinibapproved, new study

Their studies: Sanofi’s studies of Gastrointestinal Stromal Tumors in search

–
Geographic Atrophy2 of 3 · compare here–

Sanofi in Geographic Atrophy: 1 program

  1. SAR446597phase 2

Their studies: Sanofi’s studies of Geographic Atrophy in search

Novartis in Geographic Atrophy: 1 program

  1. FWY003phase 2

Their studies: Novartis’s studies of Geographic Atrophy in search

Kidney Diseases2 of 3 · compare here

GlaxoSmithKline in Kidney Diseases: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Kidney Diseases in search

–

Novartis in Kidney Diseases: 1 program

  1. Atrasentanphase 3

Their studies: Novartis’s studies of Kidney Diseases in search

Liver Cirrhosis, Biliary2 of 3 · compare here

GlaxoSmithKline in Liver Cirrhosis, Biliary: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Liver Cirrhosis, Biliary in search

Sanofi in Liver Cirrhosis, Biliary: 1 program

  1. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Liver Cirrhosis, Biliary in search

–
Lymphoma2 of 3 · compare here

GlaxoSmithKline in Lymphoma: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma in search

–

Novartis in Lymphoma: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma in search

Lymphoma, Non-Hodgkin2 of 3 · compare here

GlaxoSmithKline in Lymphoma, Non-Hodgkin: 1 program

  1. GSK5926371phase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma, Non-Hodgkin in search

–

Novartis in Lymphoma, Non-Hodgkin: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Non-Hodgkin in search

Macular Degeneration2 of 3 · compare here–

Sanofi in Macular Degeneration: 1 program

  1. SAR402663phase 2

Their studies: Sanofi’s studies of Macular Degeneration in search

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

Meningitis, Meningococcal2 of 3 · compare here

GlaxoSmithKline in Meningitis, Meningococcal: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Meningitis, Meningococcal in search

Sanofi in Meningitis, Meningococcal: 1 program

  1. MenACYW conjugate vaccineapproved, new study

Their studies: Sanofi’s studies of Meningitis, Meningococcal in search

–
Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

GlaxoSmithKline in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–

Novartis in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Prostatic Neoplasms, Castration-Resistant2 of 3 · compare here

GlaxoSmithKline in Prostatic Neoplasms, Castration-Resistant: 1 program

  1. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Prostatic Neoplasms, Castration-Resistant in search

–

Novartis in Prostatic Neoplasms, Castration-Resistant: 1 program

  1. luxdegalutamidephase 2

Their studies: Novartis’s studies of Prostatic Neoplasms, Castration-Resistant in search

Pruritus2 of 3 · compare here

GlaxoSmithKline in Pruritus: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Pruritus in search

–

Novartis in Pruritus: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Pruritus in search

Pulmonary Arterial Hypertension2 of 3 · compare here–

Sanofi in Pulmonary Arterial Hypertension: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Pulmonary Arterial Hypertension in search

Novartis in Pulmonary Arterial Hypertension: 1 program

  1. LTP001phase 2

Their studies: Novartis’s studies of Pulmonary Arterial Hypertension in search

Scleroderma, Diffuse2 of 3 · compare here–

Sanofi in Scleroderma, Diffuse: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Scleroderma, Diffuse in search

Novartis in Scleroderma, Diffuse: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Scleroderma, Diffuse in search

Spondylitis, Ankylosing2 of 3 · compare here–

Sanofi in Spondylitis, Ankylosing: 1 program

  1. sarilumabapproved, new study

Their studies: Sanofi’s studies of Spondylitis, Ankylosing in search

Novartis in Spondylitis, Ankylosing: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Spondylitis, Ankylosing in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 65 of 88 · Sanofi 53 of 80 · Novartis 56 of 77 programs (42 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, Sanofi: 12, Novartis: 7).